PYX-201
- Generic Name
- PYX-201
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PYX-201 is an antibody-drug conjugate directed against the extra domain-B splice variant of fibronectin.
- Associated Conditions
- -
- Associated Therapies
- -
Pyxis Oncology price target lowered to $5 from $7 at H.C. Wainwright
H.C. Wainwright reduces Pyxis Oncology's (PYXS) price target to $5 from $7, maintaining a Buy rating. Pyxis shifts focus from PYX-106 to PYX-201, its lead antibody-drug conjugate, due to Siglec-15's questionable potential, aiding in operational expense management and PYX-201 development focus.
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Pyxis Oncology prioritizes PYX-201, a novel ADC showing promise in HNSCC and other solid tumors, with a 50% ORR in HNSCC patients. Current funding supports development into 2H 2026. PYX-106 deprioritized to focus resources on PYX-201, with trials expected to begin in early 2025.
Pyxis Oncology's SWOT analysis: ADC developer's stock shows promise amid trials
Pyxis Oncology, focused on ADCs for cancer treatment, has a strong liquidity position and is progressing with its lead candidate, PYX-201, showing efficacy across six tumor types. The company's market cap is $96.33M, with analyst targets ranging from $7 to $13. Success of PYX-201 could double the share price, but safety concerns and competitive ADC landscape pose risks.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath